Financed by venture capitalists and backed by a board of marquee scientists, Elysium Health executives scored a key negotiation tool with chemical giant W.R. Grace in 2016: a confidential sales spreadsheet from Elysium’s then-supplier that showed Elysium was the dominate purchaser of a key ingredient in anti-aging supplements.

Mark Morris acknowledges he got the information on international sales of nicotinamide riboside through his job at ChromaDex, and he gave it to his new colleagues at Elysium as they prepared for a meeting aimed at edging ChromaDex out of the deal and establishing a direct purchasing agreement with Grace. The gift followed months of similar leaks that were peppered with icy wishes for the ChromaDex co-workers Morris planned to leave behind.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]